ClinicalTrials.gg
CompletedNCT07478133Updated Mar 17, 2026

Bioequivalence Study of Nalfurafine Hydrochloride Orally Disintegrating Tablets on Fasting and Fed in Humans

An interventional study of Nalfurafine Hydrochloride Orally Disintegrating Tablets and Remitch® in Pruritus, sponsored by Shandong New Time Pharmaceutical Co., LTD. Completed at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Shandong New Time Pharmaceutical Co., LTD (part of Lunan Pharmaceutical Group) · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 2 years 9 months after the study started (first participant enrolled May 2023, registered Mar 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing TRK 820 in Pruritus — 3 open to participants now, 3 under way, none of them phase 3. TRK 820 · Pruritus.

Enrollment
7th of 10
72 · median 99
Started
2023
the only one that year
No phase
3 of 10
2 open now
Registered
8th of 10
by date
Lead sponsor
1 of 10
Shandong New Time Pharmaceutical Co., LTD

Among the 10 studies testing TRK 820 in Pruritus, this one is the 7th largest by enrollment, is the only one that started in 2023, is one of 3 with no phase, and was the 8th registered.

Pruritus

491 studies on the registry are indexed under Pruritus; 94 are open to participants now.

Browse Pruritus studies →

Open to participants now

3 of the 10 studies testing TRK 820 in Pruritus are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About TRK 820

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing TRK 820 in Pruritus, or all of them as a file.
02

Study summary

The test formulation of Nalfurafine Hydrochloride Orally Disintegrating Tablets (2.5 μg) is bioequivalent to the reference formulation (Remitch®) in healthy Chinese subjects under fed conditions.

Read the detailed description

This is a single-center, randomized, open-label, single-dose, two-formulation, two-sequence crossover study designed to evaluate the bioequivalence and safety of a generic formulation versus the reference formulation of Nalfurafine Hydrochloride Orally Disintegrating Tablets (2.5 μg) in healthy Chinese male and female subjects under fed conditions. A planned total of 72 eligible subjects will be enrolled. Venous blood samples are collected for the determination of plasma concentrations of nalfurafine. In each study period, samples are taken at pre-dose (0#h) and at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5,4, 4.5, 5, 6, 8, 10, 12, 24, and 36 #h post-dose.

03

Conditions studied

  • Pruritus

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate and sign the form, with the informed consent process complying with GCP requirements;
  2. Healthy male or female;
  3. Aged 18 years or older;
  4. Female body weight ≥45.0 kg, male body weight ≥50.0 kg, with (BMI) = weight (kg) / height² (m²), and BMI within the range of 19.0-26.0 kg/m², inclusive.

Exclusion criteria

Exclusion Criteria:

  1. A history or current presence of abnormalities in the motor system, nervous system, mental system, endocrine system, blood circulation system, respiratory system, digestive system, urinary system, or reproductive system, which is deemed by the investigator;
  2. Undergone surgery within 3 months prior to screening or during the screening period, or undergone surgery that affects drug absorption, distribution, metabolism, or excretion, or planned surgery during the study period;
  3. A history of habitual constipation;
  4. Chronic insomnia or a habit of taking sleeping pills;
  5. Blood donation or significant blood loss (≥400 mL) within 3 months prior to screening or during the screening period (excluding physiological blood loss in women);
  6. A history of drug abuse within the past 5 years or a positive result in drug screening;
  7. A specific allergy history (asthma, urticaria, eczema, etc.), or allergies to drugs, environments, foods, or known allergy to the components or analogs of this drug;
  8. Excessive consumption of tea, coffee, or caffeinated beverages within 3 months prior to screening (more than 8 cups per day, 1 cup = 250 mL), or intake of any food or beverage containing alcohol, caffeine, or xanthine-rich substances (such as coffee, strong tea, chocolate, cola, grapefruit, etc.) within 48 hours before taking the drug;
  9. Alcohol abuse within 3 months prior to screening (consuming more than 14 units of alcohol per week: 1 unit ≈ 285 mL of beer, 25 mL of spirits, or 100 mL of wine), unwillingness to abstain from alcohol during the study, or an alcohol breath test result > 0 mg/100 mL;
  10. Smoking ≥5 cigarettes per day within 3 months prior to screening or unwillingness to quit smoking during the study;
  11. Inability to adhere to a uniform diet or difficulty swallowing;
  12. Intolerance to standard meals or lactose intolerance (e.g., diarrhea after consuming milk);
  13. Use of any prescription drugs, over-the-counter medications, herbal medicines, or health supplements within 14 days prior to screening;
  14. Use of any drugs that inhibit or induce liver metabolism of drugs within 28 days prior to screening;
  15. Vaccination within 28 days prior to screening or planned vaccination during the study period;
  16. Participation in another clinical trial and use of investigational drugs or devices within 3 months prior to screening, or planned participation in other clinical trials during this study, or participation in clinical trials not conducted in person;
  17. Pregnant or breastfeeding women, or male subjects (or their partners) or female subjects with pregnancy plans within 2 weeks prior to screening to 3 months after the study, or unwillingness to adopt a medically recognized non-drug method (such as intrauterine devices or condoms) during the study;
  18. Difficulty in blood collection, a history of needle phobia or blood phobia, or inability to tolerate venous puncture;
  19. Abnormalities in physical examination, blood routine, blood biochemistry, urine routine, 12-lead , coagulation function, infectious disease screening, or pregnancy test (applicable to female subjects) that are clinically significant;
  20. Abnormal vital signs that remain abnormal after re-examination;
  21. Subjects deemed unsuitable for enrollment by the investigator or those who withdraw for personal reasons.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Fasting

    Healthy male and female subjects will be randomized to receive a single oral dose of the Test and Reference formulations under fasting conditions, according to a two-period, two-sequence crossover design with a 7-day washout period between periods.

    Drug: Nalfurafine Hydrochloride Orally Disintegrating Tablets · Drug: Remitch®

  • Experimental
    Fed

    Healthy male and female subjects will be randomized to receive a single oral dose of the Test and Reference formulations under fed conditions (30 minutes after a high-fat, high-calorie meal), according to a two-period, two-sequence crossover design with a 7-day washout period between periods. The two arms (fasting and fed) are conducted in parallel without crossover between arms.

    Drug: Nalfurafine Hydrochloride Orally Disintegrating Tablets · Drug: Remitch®

Interventions

  • DrugNalfurafine Hydrochloride Orally Disintegrating Tablets

    Test Product. Manufacturer: Shandong New Time Pharmaceutical Co., Ltd. Dosage Form/Strength: 2.5 μg tablet Administration: Single oral dose of 2.5 μg (1 tablet).

  • Reference Product. Manufacturer: Toray Co. Ltd. Form/Strength: 2.5 μg tablet Administration: Single oral dose of 2.5 μg (1 tablet).

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax)

    Evaluation of Peak Plasma Concentration (Cmax)

    Time frame: 36 hours post-dose in each period

  2. Area under the plasma concentration versus time curve (AUC) 0-t

    plasma concentration-time curve from zero to the time of the last measurable time point t

    Time frame: 36 hours post-dose in each period

  3. Area under the plasma concentration versus time curve (AUC)0-∞

    area under the plasma concentration-time curve from zero to infinity

    Time frame: 36 hours post-dose in each period

Other outcomes

  1. maximum plasma concentration (tmax)

    time to reach the maximum plasma concentration after drug administration (tmax)

    Time frame: 36 hours post-dose in each period

  2. Incidence of Treatment-Emergent Adverse Events

    Collection of adverse events

    Time frame: 10 Days

07

Study locations

1 site
  • Jiangnan University Affiliated Hospital
    Wuxi, Jiangsu 214000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Jul 2023, 1 month.

Of 101 interventional studies with no phase under Pruritus, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2026
First posted
Mar 17, 2026
StartActual
May 24, 2023
Primary completionActual
Jul 14, 2023
CompletionActual
Jul 14, 2023
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07478133
Responsible party
Sponsor
First posted
Mar 17, 2026
Start date
May 24, 2023
Primary completion
Jul 14, 2023
Completion
Jul 14, 2023
Last update
Mar 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TRK 820

Start the discussion